Branded Advair Breathes Another Day; Mylan Says A CRL Is On The Way For A Generic
Executive Summary
FDA alerted Mylan to expect a complete response letter related to its ANDA for generic Advair. The company said it still could receive an approval prior to the standard 90-day time period after responding to the letter, because the application has a priority designation.
You may also be interested in...
Pharma Q3 Preview: Amgen, Allergan, Pfizer, GSK And Sanofi
Pfizer CEO Ian Read will preside over his last sales and earnings call as the big pharma's chief executive, while for GlaxoSmithKline, uncertainty lingers over the timing of a generic Advair. Amgen will have its second opportunity to talk to investors about its 60% Repatha price cut, while answering questions about Aimovig strategy and Neulasta biosimilars. And other topics to watch in the next earnings calls...
Mylan To Explore Strategic Options, Claiming Investors Have Failed To Appreciate The Value
CEO Heather Bresch gave a soliloquy on US health care during the second quarter call, saying ‘perverse incentives’ have created a system that ‘feeds on higher prices.’
Mylan To Explore Strategic Options, Claiming Investors Have Failed To Appreciate The Value
CEO Heather Bresch gave a soliloquy on US health care during the second quarter call, saying ‘perverse incentives’ have created a system that ‘feeds on higher prices.’